November 2024 – Page 12 – Talk Bio

Actionable Insights Powered by AI

RFK Jr.’s HHS Nomination: A Potential Threat to the Biopharma Industry

5 months ago talkbio0Tagged Administration occupational activities, Biopharma, CHARGE Syndrome, Health Policy, Industry, nomination, RFK Jr., Skepticism, Transplant Registry Unified Management Program, Vaccines

RFK Jr., HHS nomination, biopharma industry, vaccine skepticism, health policies, Trump administration

Dupixent (Dupilumab) Advances Towards FDA Approval for Chronic Spontaneous Urticaria (CSU) in 2025

5 months ago talkbio0Tagged Biologic Medicine, Chronic Spontaneous Urticaria, dupilumab, Dupixent, Inflammation, Regeneron, Review [Publication Type], sanofi, United States Food and Drug Administration

Dupixent, Dupilumab, Chronic Spontaneous Urticaria (CSU), FDA Review, Sanofi, Regeneron, Biologic Medicine, Type 2 Inflammation, H1 Antihistamines

Sensei Biotherapeutics Announces Major Restructuring: 46% Workforce Reduction and Closure of Rockville Research Site

5 months ago talkbio0Tagged Clinical Development, Organization administrative structures, Research Site Closure, restructuring, Sensei Biotherapeutics, SNS-101

Sensei Biotherapeutics, workforce reduction, research site closure, organizational restructuring, SNS-101 clinical development

Gilead Sciences and Kite Pharma Announce Layoffs, Closure of Seattle and Philadelphia Offices

5 months ago talkbio0Tagged Gilead Sciences, Industry, Kite Pharma, Office Closures, Philadelphia, restructuring, Seattle

Gilead Sciences, Kite Pharma, layoffs, office closures, Seattle, Philadelphia, biotech industry, restructuring

Bluebird Bio Confronts Financial Crunch Amidst Breakeven Projections

5 months ago talkbio0Tagged Cash, cash flow, Family Turdidae (organism), financial stability, gene therapy

Bluebird Bio, cash gap, breakeven point, financial stability, gene therapy, cash flow

Johnson & Johnson Expands Immunology Portfolio with $1.25B Acquisition of Yellow Jersey Therapeutics

5 months ago talkbio0Tagged Antibodies, Bispecific, Dermatitis, Atopic, Immunology, Johnson and Johnson, NM26, Numab, Yellow Jersey Therapeutics

Johnson & Johnson, Yellow Jersey Therapeutics, NM26, atopic dermatitis, bispecific antibody, immunology, Numab Therapeutics

BeiGene Rebrands as BeOne Medicines, Emphasizing Global Unity Against Cancer

5 months ago talkbio0Tagged BeiGene, Changing, Global Oncology, Malignant Neoplasms, Strategic Growth

BeiGene, BeOne Medicines, Global Oncology, Cancer Treatment, Name Change, Strategic Growth

FDA Approves PTC Therapeutics’ Kebilidi, the First Gene Therapy Delivered Directly to the Brain for AADC Deficiency

5 months ago talkbio0Tagged Approved, Brain-Delivered Therapy, DDC gene, Deficiency, factor IX, gene therapy, Hereditary Diseases, Kebilidi, United States Food and Drug Administration

PTC Therapeutics, Kebilidi, Gene Therapy, AADC Deficiency, FDA Approval, Brain-Delivered Therapy, Rare Genetic Disorder

GUBamy, a Weekly Amylin Agonist, Shows Promising Weight Loss and Tolerability in Phase 1 Trial

5 months ago talkbio0Tagged Agonist, Amylin, GUBamy, long-acting, Obesity, phase 1 trial, Weight Loss

Amylin agonist, Obesity treatment, Weight loss, Phase 1 trial, GUBamy, Long-acting amylin agonist

Adaptimmune Prepares for Next FDA Submission Following Success in Pivotal Sarcoma Study

5 months ago talkbio0Tagged Adaptimmune, Afami-cel, Cancer Therapeutic Procedure, Cell Therapy, Sarcoma, Submission, synovial sarcoma, United States Food and Drug Administration

Adaptimmune, FDA submission, sarcoma study, afami-cel, lete-cel, cell therapy, synovial sarcoma, cancer treatment